Publication

Use of real-world evidence in pharmacoeconomic analysis: illustrations in The Netherlands and China

Huang, Y., 2019, [Groningen]: University of Groningen. 185 p.

Research output: ThesisThesis fully internal (DIV)Academic

Copy link to clipboard

Documents

  • Title and contents

    Final publisher's version, 327 KB, PDF document

  • Chapter 1

    Final publisher's version, 444 KB, PDF document

  • Chapter 2

    Final publisher's version, 1 MB, PDF document

  • Chapter 3

    Final publisher's version, 2 MB, PDF document

  • Chapter 4

    Final publisher's version, 1 MB, PDF document

  • Chapter 5

    Final publisher's version, 1 MB, PDF document

  • Chapter 6

    Final publisher's version, 2 MB, PDF document

    Embargo ends: 16/09/2020

    Request copy

  • Chapter 7

    Final publisher's version, 1 MB, PDF document

  • Summary

    Final publisher's version, 468 KB, PDF document

  • Appendices

    Final publisher's version, 702 KB, PDF document

  • Complete thesis

    Final publisher's version, 5 MB, PDF document

    Embargo ends: 16/09/2020

    Request copy

  • Propositions

    Final publisher's version, 543 KB, PDF document

DOI

  • Yunyu Huang
The main objective of the thesis is to assess the added value of use of observational data in pharmacoeconomic (PE) evaluations. Five sub-aims were addressed in the thesis:
1) a systematic literature review summarized results evidencing the cost-saving potentials of renin-angiotensin-aldosterone system (RAAS) inhibitors, including angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blockers (ARBs), in type 2 diabetes (T2D) patients with nephropathy compared with conventional therapy excluding a RAAS inhibitor;
2) a general framework was developed to illustrate the problems and solutions of data quality assessment and preprocessing, based on the ‘fit-for-use’ concept;
3) a comparative effectiveness study compared the effectiveness of ACE inhibitors vs. ARBs for protecting T2D patients from renal function decline in a real-world setting, the value of observational data in outcomes research studies was assessed;
4) a real-world study described the changes of diabetes cost in Chinese patients using electronic claims data, and the value of observational data in health economics studies was assessed;
5) a cost-effectiveness analysis of RAAS inhibitors (ACE inhibitors and ARBs) vs. other active anti-hypertensive agents and no anti-hypertensive treatment in patients with T2D and nephropathy in China was performed from a healthcare payer perspective, and a budget impact analysis was conducted alongside the PE evaluation to analyze the budget changes of Chinese urban employee basic medical insurance (UEBMI) when different strategies of medication use are applied; the use of observational data in PE evaluations was assessed.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Supervisors/Advisors
Award date16-Sep-2019
Place of Publication[Groningen]
Publisher
Print ISBNs978-94-034-1870-4
Electronic ISBNs978-94-034-1869-8
Publication statusPublished - 2019

Download statistics

No data available

ID: 95669767